Domov › Nadváha › Arizona › Phoenix
Klinické štúdie Nadváha v meste Phoenix, AZ
15 štúdií pre Nadváha hľadá účastníkov v zariadeniach v meste Phoenix a okolí (do cca 30 míľ). Otvorte štúdiu a zistite, kto sa môže zapojiť a ako kontaktovať tím.
Oficiálny text štúdie (anglicky)
Hľadáte účastníkov do štúdie? Zvýraznite ju na začiatku tejto stránky – $99 na 30 dní →
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Prebieha náborFáza 3
- Absolute Clinical Research, Phoenix
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
Prebieha náborFáza 3
- RIO Clinical Trials - Phoenix, Phoenix
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
Prebieha náborFáza 3
- Research Site, Phoenix
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Prebieha náborFáza 3
- Synexus Clinical Research US, Inc., Phoenix
- Medical Advancement Centers of Arizona, Phoenix
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
Prebieha náborFáza 3
- Elite Clinical Studies, LLC, Phoenix
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
Prebieha náborFáza 3
- AURORA-1 Clinical Site, Phoenix
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Prebieha náborFáza 3
- AURORA-2 Clinical Site, Phoenix
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
Prebieha náborFáza 2
- Helios Clinical Research - Phoenix, Phoenix
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Prebieha náborFáza 3Vítaní zdravých dobrovoľníkov
- ACCOMPLISH-2 Research Site, Phoenix
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
Prebieha náborFáza 2
- Synexus Clinical Research US, Inc., Phoenix
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
Prebieha náborFáza 4
- Medical Dermatology Specialists, Phoenix
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
Prebieha náborFáza 3
- Kailera Clinical Site, Phoenix
Redefining Evaluation of Adiposity and Leanness: Broadening Objective Diagnostics for Obesity
Prebieha náborObservačná štúdia
- Exponent Phoenix, Phoenix
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
Prebieha náborFáza 3
- ACCOMPLISH-1 Research Site, Phoenix
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
Prebieha náborFáza 3
- The University of Arizona College of Medicine- Phoenix, Phoenix
Štúdie Nadváha v iných mestách
- San Antonio, TX34 štúdií
- Houston, TX33 štúdií
- Chicago, IL28 štúdií
- Orlando, FL27 štúdií
- Las Vegas, NV23 štúdií
- Miami, FL23 štúdií
- Atlanta, GA20 štúdií
- Dallas, TX20 štúdií
- New York City, NY19 štúdií
- Jacksonville, FL19 štúdií
- Washington, DC19 štúdií
- Austin, TX18 štúdií
Iné štúdie v Phoenix
- Rakovina prsníka25 štúdií
- Kolorektálny karcinóm25 štúdií
- Obézita22 štúdií
- Nemalobunkový karcinóm pľúc20 štúdií
- Metastatická rakovina20 štúdií
- Srdcové zlyhanie18 štúdií
- Rakovina prostaty17 štúdií
- Rakovina (všetky typy)17 štúdií
- Mnohonásobný myelóm16 štúdií
- Rakovina pankreasu16 štúdií
- Kardiovaskulárne ochorenia16 štúdií
- Alzheimerova choroba15 štúdií
Z ClinicalTrials.gov, dáta načítané 5. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.